HIV-1 Subtype Distribution and Its Demographic Determinants in Newly Diagnosed Patients in Europe Suggest Highly Compartmentalized Epidemics

Background: Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.

Results: We investigated the subtype distribution of HIV-1 in Europe and Israel in a representative sample of patients diagnosed between 2002 and 2005 and related it to the demographic data available. 2793 PRO-RT sequences were subtyped either with the REGA Subtyping tool or by a manual procedure that included phylogenetic tree and recombination analysis. The most prevalent subtypes/CRFs in our dataset were subtype B (66.1%), followed by sub-subtype A1 (6.9%), subtype C (6.8%) and CRF02_AG (4.7%). Substantial differences in the proportion of new diagnoses with distinct subtypes were found between European countries: the lowest proportion of subtype B was found in Israel (27.9%) and Portugal (39.2%), while the highest was observed in Poland (96.2%) and Slovenia (93.6%). Other subtypes were significantly more diagnosed in immigrant populations. Subtype B was significantly more diagnosed in men than in women and in MSM > IDUs > heterosexuals. Furthermore, the subtype distribution according to continent of origin of the patients suggests they acquired their infection there or in Europe from compatriots.

Conclusions: The association of subtype with demographic parameters suggests highly compartmentalized epidemics, determined by social and behavioural characteristics of the patients.

Citing Articles

Defective proviruses significantly impact viral transcription and immune activation in men and women with HIV-1 subtype C in rural South Africa.

Buchholtz N, Hermans L, Umunnakwe C, Nuhn M, Voss R, Need E Front Immunol. 2024; 15:1484358.

PMID: 39660138 PMC: 11628515. DOI: 10.3389/fimmu.2024.1484358.

Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.

Wieczorek L, Chang D, Sanders-Buell E, Zemil M, Martinez E, Schoen J Virol J. 2024; 21(1):148.

PMID: 38951814 PMC: 11218331. DOI: 10.1186/s12985-024-02394-y.

The Role of Late Presenters in HIV-1 Transmission Clusters in Europe.

Miranda M, Pimentel V, Gomes P, do Rosario O Martins M, Seabra S, Kaiser R Viruses. 2023; 15(12).

PMID: 38140659 PMC: 10746990. DOI: 10.3390/v15122418.

Consequences of HIV infection in the bone marrow niche.

Herd C, Mellet J, Mashingaidze T, Durandt C, Pepper M Front Immunol. 2023; 14:1163012.

PMID: 37497228 PMC: 10366613. DOI: 10.3389/fimmu.2023.1163012.

Transmitted HIV-1 is more virulent in heterosexual individuals than men-who-have-sex-with-men.

James A, Dixit N PLoS Pathog. 2022; 18(3):e1010319.

PMID: 35271687 PMC: 8912199. DOI: 10.1371/journal.ppat.1010319.

References

Fox J, Castro H, Kaye S, McClure M, Weber J, Fidler S . Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 2010; 24(15):2397-401. DOI: 10.1097/QAD.0b013e32833cbb5b. View

Masur H, Michelis M, Greene J, Onorato I, Stouwe R, Holzman R . An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981; 305(24):1431-8. DOI: 10.1056/NEJM198112103052402. View

Palma A, Covens K, Snoeck J, Vandamme A, Camacho R, Van Laethem K . HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G. J Antimicrob Chemother. 2012; 67(5):1075-9. DOI: 10.1093/jac/dks010. View

. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008; 22(5):625-35. DOI: 10.1097/QAD.0b013e3282f5e062. View

Bannister W, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J . HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther. 2007; 11(6):707-15. View

Baeten J, Chohan B, Lavreys L, Chohan V, McClelland R, Certain L . HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007; 195(8):1177-80. DOI: 10.1086/512682. View

Plantier J, Leoz M, Dickerson J, De Oliveira F, Cordonnier F, Lemee V . A new human immunodeficiency virus derived from gorillas. Nat Med. 2009; 15(8):871-2. DOI: 10.1038/nm.2016. View

Gottlieb M, Schroff R, Schanker H, Weisman J, Fan P, Wolf R . Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981; 305(24):1425-31. DOI: 10.1056/NEJM198112103052401. View

Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele B, Liu W . Human immunodeficiency viruses: SIV infection in wild gorillas. Nature. 2006; 444(7116):164. DOI: 10.1038/444164a. View

10.

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011; 25(5):679-89. PMC: 3755761. DOI: 10.1097/QAD.0b013e328342ff93. View

11.

Yang C, Li M, Newman R, Shi Y, Ayisi J, van Eijk A . Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS. 2003; 17(11):1667-74. DOI: 10.1097/01.aids.0000060412.18106.d4. View

12.

Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F . Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008; 197(5):707-13. DOI: 10.1086/527416. View

13.

Palma A, Araujo F, Duque V, Borges F, Paixao M, Camacho R . Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol. 2007; 7(3):391-8. DOI: 10.1016/j.meegid.2007.01.009. View

14.

van de Vijver D, Wensing A, Angarano G, Asjo B, Balotta C, Boeri E . The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr. 2006; 41(3):352-60. DOI: 10.1097/01.qai.0000209899.05126.e4. View

15.

Abecasis A, Deforche K, Bacheler L, McKenna P, Carvalho A, Gomes P . Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther. 2006; 11(5):581-9. View

16.

Abecasis A, Vandamme A, Lemey P . Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol. 2009; 83(24):12917-24. PMC: 2786833. DOI: 10.1128/JVI.01022-09. View

17.

Vercauteren J, Wensing A, van de Vijver D, Albert J, Balotta C, Hamouda O . Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009; 200(10):1503-8. DOI: 10.1086/644505. View

18.

Sharp P, Bailes E, Chaudhuri R, Rodenburg C, Santiago M, Hahn B . The origins of acquired immune deficiency syndrome viruses: where and when?. Philos Trans R Soc Lond B Biol Sci. 2001; 356(1410):867-76. PMC: 1088480. DOI: 10.1098/rstb.2001.0863. View

19.

Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D . Diversity considerations in HIV-1 vaccine selection. Science. 2002; 296(5577):2354-60. DOI: 10.1126/science.1070441. View

20.

Kunanusont C, Foy H, Kreiss J, Rerks-Ngarm S, Phanuphak P, Raktham S . HIV-1 subtypes and male-to-female transmission in Thailand. Lancet. 1995; 345(8957):1078-83. DOI: 10.1016/s0140-6736(95)90818-8. View